We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ITOC:NASDAQiTonic Holdings Ltd Analysis

Data as of 2026-06-03 - not real-time

$0.29

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Technical outlook: The stock is trading just above a key support level and below both its 20‑day and 50‑day simple moving averages, signaling a bearish price trend. Momentum indicators such as the RSI are in the lower‑mid range, suggesting limited upside momentum, while the MACD histogram remains negative, reinforcing the bearish bias. Trading volume has been on a decline and the 30‑day price volatility is exceptionally high, indicating a fragile market environment. The beta well above two points to amplified moves relative to the broader market, increasing the risk of sharp price swings.
Fundamental outlook: Revenue has surged nearly double year‑over‑year, but the company continues to post operating losses and negative cash flow, eroding profitability. A modest cash buffer exists against a relatively small debt load, yet the book‑value per share exceeds the current market price, making the stock appear undervalued on a price‑to‑book basis. The recent Nasdaq notice granting a 180‑day extension to meet the minimum bid‑price rule highlights ongoing compliance pressure. Combined with high sector and geographic risks, the overall picture is one of speculative upside potential tempered by significant downside hazards.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish technical setup with price below key moving averages
  • Nasdaq compliance extension indicating near‑term delisting risk
  • Low and decreasing trading volume limiting liquidity

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth offering a potential turnaround
  • Undervalued price‑to‑book ratio providing a margin of safety
  • Continued cash burn and negative operating margins limiting confidence

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Revenue expansion in a niche medical‑device market
  • Potential for regulatory approvals to improve profitability
  • Undervalued valuation metrics relative to book value

Key Metrics & Analysis

Financial Health

Revenue Growth91.60%
ROE-71.25%
ROA-40.98%
Debt/Equity1.76
P/B Ratio0.8
Op. Cash Flow$-3231427
Free Cash Flow$-902183
Industry P/E27.2

Technical Analysis

TrendBearish
RSI39.1
Support$0.28
Resistance$0.36
MA 20$0.30
MA 50$0.32
MA 200$0.51
MACDBearish
VolumeDecreasing
Fear & Greed Index92.75

Valuation

GradeUndervalued
TypeBlend

Risk Assessment

Beta2.00
Volatility83.66%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.